New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:51 EDTIMUCImmunoCellular upgraded at Roth Capital
As previously reported, Roth Capital upgraded ImmunoCellular to Buy from Neutral. The firm upgraded shares following the update to the the Phase II ICT-107 study in front-line glioblastoma. The analyst believes a true addressable patient population has been identified and is optimistic on the next regulatory steps. Price target raised to $3 from $2.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
16:29 EDTIMUCImmunoCellular appoints Dr. Swanson to lead Stem-to-T-cell research program
ImmunoCellular Therapeutics announced the appointment of Steven Swanson, PhD, as SVP, Research. Dr. Swanson will lead the company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Prior to joining ImmunoCellular, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bioanalytical procedures, immunogenicity assessment, regulatory affairs and product quality.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use